• NewAmsterdam Pharma recently announced it will present multiple new data sets on its drug candidate obicetrapib at the 2026 Alzheimer’s Association International Conference, highlighting its potential as an oral, low-dose therapy for early Alzheimer’s prevention and sharing analyses from the BROADWAY trial.
• An interesting angle for investors is that obicetrapib, originally developed for cardiovascular disease, is being explored for Alzheimer’s prevention through multi-pathway effects, including biomarkers such as P‑tau217 and ApoE4-dependent responses.
• With encouraging safety data and a focus on obicetrapib’s multi-pathway role in early Alzheimer’s prevention, we’ll assess how this shapes NewAmsterdam Pharma’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is NewAmsterdam Pharma's Investment Narrative?

For NewAmsterdam Pharma, the core belief as a shareholder is that obicetrapib can become a meaningful commercial product in cardiovascular disease, with the Alzheimer’s prevention work emerging as an upside option rather than the main pillar. The AAIC 2026 presentations fit into that story by broadening the drug’s scientific footprint, but they do not change the near-term reality that the key catalysts still sit in regulatory progress and commercial execution around LDL lowering, particularly in Europe with Menarini and eventual decisions on the validated EMA applications. In the short run, this Alzheimer’s data looks more supportive than transformative, especially against a backdrop of continuing losses and a share price that has already run strongly over the last year. The biggest risks remain trial, regulatory and commercialization setbacks, plus ongoing cash burn.

However, one issue in the background may matter more than many investors currently appreciate. NewAmsterdam Pharma's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Across three fair value estimates from the Simply Wall St Community, views stretch from about US$49.62 to a very large upper bound, underscoring just how far apart expectations can be. Set against this, the near term still hinges on obicetrapib’s regulatory path and NewAmsterdam’s ability to fund persistent losses, which could be decisive for how the story ultimately plays out.

Explore 3 other fair value estimates on NewAmsterdam Pharma - why the stock might be a potential multi-bagger!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your NewAmsterdam Pharma research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free NewAmsterdam Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NewAmsterdam Pharma's overall financial health at a glance.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.